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ABSTRACT
In this study, we report a miRNA122a based targeted gene therapy for 
hepatocellular cancer stem cells (CSCs). First, we assessed the levels of miRNA122a 
in normal human hepatocytes, a panel of hepatocellular carcinoma (HCC) cell 
lines and hepatocellular CSCs observing its significant downregulation in HCC and 
CSCs. The miRNA122a binding site was then incorporated at the 3’-UTR of reporter 
genes gaussia luciferase (GLuc) and eGFP which resulted in significant hepatocyte 
detargeting. Using this strategy for the delivery of gene directed enzyme prodrug 
therapy (GDEPT) utilizing the cytosine deaminase/5-fluorocytosine (CD/5-FC) 
system, we showed significant killing in cells with low or no miRNA122a while those 
cells, such as hepatocytes with high miRNA122a were largely spared. Next, we 
showed that CSC enriched tumorspheres exhibit a significant downregulation of 
miRNA122a expression providing a rational to exploit its binding site for targeted 
gene delivery. Using plasmids harboring reporters GLuc and eGFP with or without 
miR122a binding sites, we showed high reporter expression in the CSCs and little 
reported expression in the non-enriched cultures. Finally, we demonstrate the efficacy 
of miRNA122a based post-transcriptionally targeted GDEPT for hepatocellular CSCs. 
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INTRODUCTION
Hepatocellular carcinoma (HCC) is the most 
prevalent form of primary malignancy in the liver and is 
the third leading cause of cancer related death worldwide 
[1, 2]. Currently, effective therapeutic treatment options 
for HCC are extremely limited. Liver transplantation and 
resection have the potential to be curative but are limited 
to early stage disease [3]. Less than 20% of HCC patients 
are diagnosed with early stage tumors [4]. Treatments for 
the vast majority of patients with unresectable tumors are 
largely palliative with recurrence often observed after 
therapeutic interventions [5]. 
Cancer stem cells (CSCs) represent a subpopulation 
of cancer cells with innate resistance to radio and 
chemotherapies and are vital for tumor progression and 
recurrence after therapy [6, 7]. Accumulating evidences 
suggest that a small subset of HCC possess these stem like 
properties and thus are important targets for therapeutic 
interventions [8]. Current strategies to target HCC derived 
CSCs include targeting cell surface markers like (e.g. 
CD133, CD44) [9], blocking pathways required for CSC 
survival (e.g. PI3K/AKT, Oct4) and self-renewal (Wnt, 
Notch, TGF-β) [8], targeting the tumor microenvironment 
[10], and induction of differentiation CSC differentiation 
[11] either with chemical compounds or nanoparticles 
[12]. In this study we use a targeted gene therapy approach 
to target the CSC population. Gene therapy has undergone 
a renaissance in the past few years boosted by the approval 
of gene therapy based drugs by both the European Union 
(EU) [13] as well as the Food and Drug Administration 
(FDA) [14]. Designing strategies to deliver therapeutic 
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genes to the hepatocellular CSC population is a new and 
important approach for HCC therapy. 
microRNAs (miRNAs) are small non-coding 
RNA molecules which post-transcriptionally regulate 
the expression of genes that are involved in a variety of 
cellular functions including development, maintenance 
and/or elimination of cancer stem cells by binding to its 
complementary site usually present at the 3′-UTR of the 
corresponding gene. A number of miRNAs have been 
reported to be dysregulated in HCC derived CSC [15]. 
miRNA122, accounting for about 70% of the total miRNA 
pool, has been reported to be significantly downregulated 
in HCC [16] and HCC derived CSCs [17]. Synthetic 
mimic miRNA and miRNA inhibitors are currently 
being tested in preclinical and clinical trials for various 
diseases including HCC [18, 19]. The use of miRNA 
as a therapeutic approach may, however, have inherent 
risks, the largest being its propensity to induce off-target 
silencing of non-related genes [20, 21]. As an alternative 
to the use of mimics and inhibitors to alter the expression 
of miRNA122a, the downregulation of miRNA122a in 
HCC and HCC derived CSC provides an opportunity for 
specific therapeutic gene delivery by incorporating its 
binding site at the 3’-UTR of a therapeutic gene [22].
In this study, we demonstrate the utility of 
a miRNA122a based strategy to target HCC and 
hepatocellular CSCs for gene delivery which is pivotal for 
targeted cancer gene therapy. We show that hepatocellular 
CSCs exhibit significant downregulation of miRNA122a 
and that including the miRNA122a binding site into the 3’-
UTR of a vector results in significant hepatocyte detargeting 
and subsequent targeting of HCC and hepatocellular CSCs. 
RESULTS
miRNA122a is downregulated in HCC and non-
HCC cancer cell lines
We quantified the levels of expression of 
miRNA122a in primary human hepatocytes, and a panel 
of HCC and non-HCC cell lines. The copy number of 
miRNA122a was reported as copies per 1000 copies 
of human positive control. Using this method, primary 
human hepatocytes were found to contain an average of 
5655 copies of miRNA122a per 1000 copies of control 
while the expression of miRNA122a was not detected in 
HCC cell lines Hep3B, SKHep1, PLC/PRF/5, and SNU423 
(Figure 1). Similarly, the expression of miRNA122a was 
undetected in all the non-HCC cell lines examined (data 
not shown). However, HCC cell line HuH7 was found to 
be miRNA122a positive with 2130 copies of miRNA122a 
per 1000 copies of control (Figure 1). These results 
confirmed the hepatocyte-specific nature of miRNA122a 
and established its downregulation in HCC cell lines 
providing a rationale for exploiting the binding site for 
targeted gene delivery.
Inclusion of miRNA122a binding sites at the 3′-
UTR of a transgene enables efficient hepatocyte 
detargeting
We constructed expression plasmids harboring 
reporter genes GLuc and eGFP with 3 miRNA122a binding 
sites at the 3′-UTR. These plasmids were transfected in 
miRNA122a positive primary hepatocytes and HuH7 
cell line as well as miRNA122a negative HCC and non-
HCC cell lines. It was predicted that, in the miRNA122a 
positive cells, the reporter mRNA with miRNA122 
binding sites would be transported to the cytoplasm where 
it can interact with endogenous miRNA122 induced RISC 
complexes by sequence complementary binding resulting 
in translational repression (Figure 2A). In cells that do 
not have endogenous miRNA122a (such as HCC), there 
is predicted to be no binding to the miRNA sites on the 
transgene and translation would occur uninhibited. 
When we examined this experimentally, the relative 
luciferase expression (normalized to CMV-GLuc) was 
significantly inhibited in primary human hepatocytes after 
transfection with CMV-GLuc-miR122a*3 (p < 0.001) 
(Figure 2B, 2C). Similarly, a 55% reduction in luciferase 
expression was observed in HuH7 cell line (p < 0.001) 
(Figure 2D). In contrast, the miRNA122a negative HCC 
and non-HCC cell lines displayed no significant differences 
in luciferase expression (Figure 2D and 2E). 
Inhibition of miRNA122a in hepatocytes rescues 
the expression of transgene containing its binding 
site at the 3′-UTR while its overexpression in 
HCC cells lead to the suppression of transgene 
expression
In order to confirm that miRNA122a expression was 
responsible for the detargeting of our vectors, we utilized 
miRNA122a inhibitors and mimics to alter miRNA 
expression in hepatocyte and HCC cell lines. Using the 
miRNA122a inhibitor, we showed a significant increase in 
luciferase expression in both primary human hepatocytes 
(Figure 3A (i)) and HepaRG (Figure 3A (ii)) following 
transfection with CMV-GLuc-miR122a*3 (p < 0.001). 
The addition of miRNA122a inhibitors did not alter the 
luciferase expression in the low/non-expressing HCC cell 
lines (data not shown). 
Using a miRNA122a mimic to increase the presence 
of miRNA in the HCC cell lines, we showed a significant 
decrease in luciferase expression following transfection 
with CMV-GLuc-122a*3 (p < 0.005). Luciferase 
expression decreased from 89.8% to 27.3%, 75% to 1.8%, 
70% to 1.7%, and 101% to 12% (p < 0.005) in HCC 
cell lines Hep3B, PLC/PRF/5, SKHep1 and SNU423 
respectively (Figure 3B). The addition of miRNA122a 
mimic did not alter the luciferase expression in the primary 
human hepatocytes (data not shown). Taken together, 
these results confirmed that the observed decrease in 
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reporter expression in miRNA122a expressing cells after 
transfection with CMV-GLuc-miR122a*3 was due to the 
action of miRNA122a.
miRNA122a regulated gene directed enzyme 
prodrug therapy (GDEPT) based on cytosine 
deaminase/5-fluorocytosine (CD/5-FC) can 
induce HCC-specific cell death
In order to study the feasibility of targeted 
GDEPT based on differential miRNA122a expression, 
we constructed vectors with the suicide gene cytosine 
deaminase (CD) and examined their ability to inhibit 
cellular proliferation and induce cytotoxicity. CD functions 
by converting the prodrug 5-FC into a cytotoxic metabolite. 
In the proliferation study, cells transfected with CMV-CD-
miR122a*3 and incubated with 5-FC were normalized 
against proliferation observed with cells transfected with 
an untargeted CMV-CD construct. The HuH7 cell line, 
expressing miRNA122a at similar levels to that of normal 
hepatocytes, transfected with CMV-CD-miR122a*3 had 
a significantly higher proliferation than those transfected 
with the untargeted CMV-CD constructs (p < 0.005) 
whereas the miRNA122a negative HCC cell lines showed 
no significant difference in proliferation (Figure 4A). 
Next, we performed flow cytometric quantification 
of cell death based on annexin/PI staining after transfection 
with CMV-CD-miR122a*3. The relative cell death of 
HuH7 after transfection with CMV-CD-miR122a*3 and 
incubation with 5-FC was significantly inhibited in HuH7 
cell line (p < 0.005), whereas no significant difference 
in cell death was observed between groups CMV-CD 
and CMV-CD-miR122a*3 in HCC cell lines Hep3B, 
PLC/PRF/5, SKHep1 (Figure 4B–4D). Taken together 
these results show that HCC with limited miRNA122a 
expression can be therapeutically targeted with CMV-CD-
miR122a*3 constructs.
miRNA122a is downregulated in cancer stem 
cells enriched HCC tumorspheres
We then investigated the miRNA122a expression 
profile in HuH7 cultures enriched for hepatocellular CSCs. 
We cultured 3D tumorspheres of HuH7 in a serum-free 
NSA media (Figure 5A) and quantified the expression 
levels of HCC stemness markers CD44 (Figure 5B), 
CD133 (Figure 5C), CD90 (Figure 5D), and Oct4 
(Figure 5E), as well as miRNA122a (Figure 5F). When 
compared to the adherent HuH7 cells, the CSC enriched 
tumorspheres of HuH7 showed a significant increase 
in the expression of hepatocellular CSC markers CD44 
(p < 0.05), CD133 (p < 0.005), CD90 (p < 0.005), and 
Oct4 (p < 0.005) (Figure 5B–5E) normalized to GAPDH 
housekeeper. Concurrent with the increase in stemness 
Figure 1: miRNA122a is downregulated in HCC and other cancer cell lines. In order to quantify the expression levels of 
miRNA122a in hepatocytes and HCC cells, we isolated total RNA from primary human hepatocytes, HepaRG cells and HCC cell lines. 
qRT-PCR was then performed to determine the number of copies of miRNA122a which was reported as copy number per 1000 copies 
of control using the formula (2^(Ct control–Ct miRNA122a))*1000. Two-tailed t-test was performed between miRNA positive cells: 
HepaRG, HUCS10P, and HuH7 and miRNA negative HCC cells individually using Graph pad prism 7.0 (n > 3, * < 0.05, *** < 0.005).
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markers, we observed a 4.34 fold decrease in expression 
of miRNA122a (p < 0.005) in HuH7 cultures enriched 
for CSCs (Figure 5F). These results suggested that under 
the culture conditions used, an enrichment of cancer stem 
cells is achieved which can be used as a model for studying 
characteristics of HCC CSCs. Furthermore, an inhibition of 
miRNA122a was observed in these HCC CSCs indicating 
a downregulation of miRNA expression in CSCs derived 
from HCC subpopulation without miRNA122a inhibition 
providing a rational for miRNA122a binding site based 
targeting of these particular CSCs.
Incorporation of miRNA122a binding site in at 
the 3’-UTR of the expression cassette can lead to 
efficient targeting of HCC cancer stem cells
Next, we investigated whether the miRNA122a 
binding site could be utilized for targeting CSCs derived 
from HCC. To do this, we transfected HuH7 and HuH7 
CSCs with CMV-eGFP-miR122a*3, and CMV-GLuc-
miR122a*3 and normalized the expression of reporters 
with CMV-eGFP and CMV-GLuc respectively. We showed 
that HuH7 cultures, enriched for CSCs, had a significant 
increase in the expression of GLuc (Figure 6A) and eGFP 
(Figure 6B–6D) with 2-fold higher GLuc expression and 
2.78-fold higher GFP expression (P < 0.05).
Finally, we examined whether HuH7 CSCs could be 
targeted and killed using CMV-CD-miR122a*3 constructs. 
We showed that HuH7 tumorspheres, when transfected 
with CMV-CD-miR122a*3 and incubated with 5-FC, 
had significantly more cell death than those cultures not 
enriched for CSCs (P < 0.05) with a 1.91 fold higher 
cell death observed (Figures 6E–6F). Collectively, these 
results suggested an efficient miRNA122a based post-
transcriptionally targeted gene therapeutic approach for 
hepatocellular CSCs. 
DISCUSSION
Rationally designed targeted gene therapy is an 
attractive therapeutic approach for diseases like HCC 
which requires a tumor specific action in order to prevent 
Figure 2: Inclusion of miRNA122a binding sites at the 3′-UTR of a transgene can inhibit its expression in hepatocytes. 
To study the effectiveness of incorporating miRNA122a binding sites at the 3′-UTR for hepatocyte detargeting, we constructed expression 
plasmids harboring GLuc reporter driven by the ubiquitous CMV promoter (CMV-GLuc) as well as plasmids harboring CMV driven reporter 
with 3 miRNA122a binding sites at the 3′-UTR (CMV-GLuc-miR122a*3). These plasmids were transfected into human hepatocytes, 
HCC, and non-HCC cell lines. (A) Shows the principles of miRNA based detargeting: In cells with endogenous miRNA122, the mRNA 
with miRNA122 binding sites is transported to the cytoplasm where it interacts with miRNA122 induced RISC complexes by sequence 
complementary binding to the seed sequence (in red). This mediates gene suppression through mRNA degradation and/or translational 
repression. In cells that do not have endogenous miRNA122a (such as HCC), there is no binding to the miRNA sites on the transgene and 
translation occurs uninhibited. (B) Primary human hepatocytes were transfected with CMV-GLuc and CMV-GLuc-miR122a*3 and the 
amount of luciferase secretion was quantified. Luciferase expression for CMV-GLuc-miR122a*3 was reported as a percentage of CMV-
GLuc for each cell type. These transfection experiments were also performed for (C) HepaRG, (D) HCC and (E) non-HCC cell lines. The 
difference between CMV-GLuc and CMV-GLuc-miR122a*3 was compared with two-tailed t-test for statistical significance using Graph 
Pad Prism. (n > 3, ***, p < 0.001).
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significant off-target effects in an already compromised 
liver. One of the different strategies for targeted gene 
delivery is the modification of the therapeutic payload 
(therapeutic gene cassette) by including disease specific 
regulatory elements like tumor specific promoters and 
miRNA binding sites [22, 23]. In recent years, there has 
been accumulating evidence demonstrating the efficacy 
of utilizing binding sites of miRNAs downregulated in 
cancers as an effective approach [24–27]. Given that 
miRNAs play a pivotal role in virtually every cellular 
pathway, it is conceivable that they are involved in the 
development and maintenance of cancer stem cells, 
thought to be responsible for resistance to chemo and 
radiotherapies as well as tumor recurrence and metastasis. 
Indeed, a number of miRNAs including miR18a, miR155, 
miR130b, miR125, miR216a/217 have roles in maintaining 
HCC stemness by targeting genes like CDX2, GATA6, 
NLK and controlling key pathways required for stemness 
[8, 28].
The well-known intra and inter-tumoral 
heterogeneity of HCC means that not all subtypes may 
have a reduced miRNA122a profile [29, 30]. When 
screening our panel of HCC cell lines, we found that 
the reduction of miRNA122a, while occurring in most 
lines, did not occur in all cell lines with HuH7 being the 
outlier. Interestingly, however, we showed that HuH7 
cultures enriched for CSCs had significantly reduced 
miRNA122a expression. The link between miRNA122a 
expression and CSC has been shown in both transgenic 
mice and cell lines. Transgenic mice with miRNA122a 
Figure 3: Inhibition of miRNA122a in hepatocytes rescues the expression of transgene with miRNA122a binding site at 
the 3′-UTR, whereas overexpression of miRNA122a in HCC cell lines inhibits it. (A) In order to study the effect of inhibition 
of miRNA122a in hepatocytes on the expression of transgene with miRNA122a binding sites, we co-transfected human hepatocytes (i) and 
HepaRG (ii) with CMV-GLuc-miR122a*3 and miRNA122a inhibitor, and CMV-GLuc and miR122a inhibitor and quantified the amount of 
luciferase secreted. The expression of luciferase was quantified for each group and expressed as a percentage of CMV-GLuc. (B) Similarly, 
HCC cell lines Hep3B, PLC/PRF/5, SKHep1, and SNU423 were co-transfected with CMV-GLuc-miR122a*3 and miRNA122a mimic, and 
CMV-GLuc and miRNA122a mimic; secreted GLuc was quantified for each group and reported as a percentage of CMV-GLuc. Two-tailed 
t-test was performed to determine the statistical significance of the observed differences between groups. (n > 3, ***p < 0.001, **p < 0.005).
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knockout have been shown to spontaneously develop HCC 
with the miRNA122a −/− tumor cells showing increased 
expression of CSC markers such as EpCAM, CD90 and 
CD133 [31]. CD133 has been shown to be a direct target 
gene of miRNA122a and its knockdown can supress 
stem-like characteristics, suggesting that miRNA122a 
may have a role in hepatocellular CSC self-renewal and 
proliferation [31]. In a recent report by Song et al. it 
was shown that CD133+ CSCs isolated from the human 
HCC cell line, PLC/PRF/5 also exhibited a significant 
reduction in miRNA122a compared to non-CSCs [17]. 
In this study they showed that in hepatocellular CSCs, 
miRNA122a plays a key role in negatively regulating 
glycolysis through its interaction with PDK4 and that the 
return of miRNA122a to the CSC population inhibits their 
stemness [17]. Given the importance of miRNA122a in 
the maintenance, development and initiation of HCC, its 
liver specificity, and differences in expression levels of 
miRNA122a in HCC and CSCs, we concluded that there 
is a strong rationale to explore the efficacy of miRNA122a 
for post-transcriptional targeting of HCC.
Exploiting the differential expression of miRNA122a 
between functional hepatocytes, HCC and hepatocellular 
CSCs, we designed vectors incorporating 3 copies of 
the binding site of miRNA122a with the goal of limiting 
expression of transgenes to those cells with reduced 
miRNA122a expression, i.e. HCC and hepatocellular 
CSCs. Using luciferase as a marker transgene, we showed 
that cells expressing miRNA122a (primary hepatocytes and 
HuH7) had a significant decrease in luciferase expression. 
Conversely, HCC cells with little or no miRNA122a had 
significantly higher luciferase expression. These results were 
in line with previous studies exploiting the miRNA122a 
binding site for efficient hepatocyte detargeting [32, 33]. 
After establishing the efficacy of miRNA122a binding site 
based targeting of HCC, we examined whether a similar 
targeting approach could be used to direct transgene 
expression to hepatocellular CSCs. To do this we utilized 
Figure 4: miRNA122a based post-transcriptionally controlled suicide gene therapy for HCC. To explore the possibility of 
performing a targeted gene directed enzyme prodrug therapy (GDEPT) utilizing cytosine deaminase/5-Fluorocytosine (CD/5-FC) system; 
we constructed CMV-CD, and CMV-CD-miR122a*3; the later consisting of 3 miRNA122a binding sites at the 3′-UTR of suicide gene 
CD. miRNA122a positive cell line HuH7 and miRNA122a negative HCC cell lines were transfected with these plasmids and subsequently 
incubated with the prodrug 5-FC. (A) The percentage proliferation was quantified with MTS assay and proliferation percentage of cells 
transfected with CMV-CD-miR122a*3 was reported as percentage of those transfected with CMV-CD. (B) Similarly, total cell death after 
suicide gene therapy with CMV-CD-miR122a*3 was quantified with flow cytometry by annexin/PI co-staining and reported as relative to 
CMV-CD. (C) Representative flow cytometric plots for each cell type showing percentage of annexin and PI positive cells after suicide 
gene therapy (D) Representative flow cytometric plot of HuH7 cell line showing annexin positive cells in the control group overlayed with 
annexin positive cells after transfection with CMV-CD and CMV-CD-miR122a*3. Two-tailed t-test was performed in Graph Pad prism to 
check for statistical significance of observed differences. (n > 3, **p < 0.005).
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Figure 5: miRNA122a is significantly downregulated in HCC stem cell enriched tumorspheres. To study the expression 
profile of miRNA122a in stem cells derived from miRNA122a positive HuH7 cell line, we maintained the cells in a stem cell enriching 
NSA media as 3D tumorspheres. (A) Phase contrast images of tumorspheres captured at day 5 after seeding HuH7 in NSA media. The cells 
were collected and total cDNA was synthesized from total cellular RNA. qRT-PCR was then performed to quantify the levels of stemness 
related genes (B) CD44, (C)CD133, and (D) CD90 (E) Oct4 which were reported as copy number per 10,000 copies of GAPDH house 
keeper using the formula (2^(Ct housekeeper- Ct sample))*10000. (F) The expression levels of miRNA122a was expressed as copy number 
per 10,000 copies of control. Difference between two groups was tested with a two-tailed t-test using Graph Pad Prism. (n > 3, *, p < 0.05, 
**, p < 0.005).
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3D tumorspheres cultures of HuH7 to enrich for CSCs [34] 
and showed increases in stemness markers and a concurrent 
downregulation of miRNA122a. The CSC enriched cultures 
were readily transfected with luciferase and eGFP vectors 
with or with the miRNA122a binding sites and showed 
enhanced transgene expression in the CSCs compared 
to the non-enriched, miRNA122a expressing cultures. 
These results confirmed that miRNA122a targeting of 
hepatocellular CSC is possible. While similar approaches 
have been used for targeting cancer including breast [35], 
glioblastoma [36, 37], fibrosarcoma [38] and HCC [32, 33], 
this is the first use of this type of approach to target CSCs.
 To explore the potential therapeutic benefit of 
using miRNA122a binding sites in HCC, we constructed 
vectors expressing the suicide gene cytosine deaminase 
(CD) with or without the miRNA binding sites (pCMV-
CD-miR122a*3 and pCMV-CD). The CD gene produces 
an enzyme that converts the non-toxic 5-FC prodrug to the 
cytotoxic 5- fluorouracil (5-FU). We found that the use of 
post-transcriptional targeting of HCC and the subsequent 
detargeting of hepatocytes using miRNA122a was both 
feasible and effective, with significantly more killing and 
the inhibition of proliferation in HCC cells. Cell death 
and inhibition of proliferation was directly related to the 
presence or absence of miRNA122a in the cells. Using 
the pCMV-CD-miR122a*3 vectors in the CSC enriched 
cultures, we also showed significant cytotoxicity in line 
with miRNA122a expression and confirmed its utility in 
targeting CSCs. By targeting CSCs with a suicide gene 
therapy approach, such as the CD/5-FC system used in this 
model, there is the potential for a double bystander effect. 
The first induced by the CD/5-FC itself, where the non-
toxic 5-FC is processed by the CSCs expressing CD into 
the toxic anabolite 5-fluorouracil (5-FU) [39]. 5-FU then 
freely diffuses across the cellular membrane and spreads 
to adjacent tumor cells that do not express the CD gene 
[39, 40]. The second bystander effect has the potential to 
remove both the bulk tumor and the CSCs [40]. Given 
that CSCs drive tumor progression and maintenance, their 
removal can result in tumor degeneration and possibly 
reduced recurrence [9]. The potential benefits of bystander 
effects inherent with the CD/5-FC system was seen in 
Figure 6: Downregulation of miRNA122a in stem cell enriched tumorspheres of HuH7 allows efficient targeting of these 
stem cell population. After observing a downregulation of miRNA122a in stem cell enriched tumorspheres of HuH7, we transfected 
the tumorspheres with (A) CMV-GLuc, and CMV-GLuc-miR122a*3 and (B) CMV-eGFP, and CMV-eGFP-miR122a*3. The amount of 
secreted luciferase after transfection with CMV-GLuc-miR122a*3 was reported as a percentage of CMV-GLuc and the percentage of GFP 
positive cells after transfection with CMV-eGFP-miR122a*3 was reported as relative to CMV-eGFP both for adherent HuH7 as well as 
HuH7 tumorspheres. (C) Representative fluorescent microscope images of HuH7 and HuH7 CSCs transfected with CMV-eGFP and CMv-
eGFP-miR122a*3 (D) Representative flow cytometry images showing GFP-positive images after transfection of HuH7 and HuH7 CSCs 
with CMV-eGFP and CMv-eGFP-miR122a*3 (E) HuH7 and HuH7 CSCs were transfected with CMV-CD, and CMV-CD-miR122a*3 and 
incubated with 5-FC containing media. Total cell death was then quantified with annexin/PI co-staining. The observed percentage total 
apoptotic cells after suicide gene therapy with CMV-CD-miR122a*3 was reported as a percentage of that with CMV-CD both for HuH7 
and HuH7 CSCs. (F) Representative flow cytometric images of HuH7, and HuH7 CSCs after suicide gene therapy showing annexin and PI 
positive cells. For statistical analysis, two-tailed t-test was performed to compare the observed differences between HuH7 and HuH7 CSCs. 
(n > 3, *, p < 0.05).
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our 3D sphere cultures, representing a solid tumor mass, 
where increased tumor killing was evident. 
The increasing knowledge of the genetic makeup of 
HCC and the CSCs derived from them allows identification 
of specific expression patterns which make them different 
from the normal liver cells. Initial work on utilising this 
knowledge for targeted gene therapy centred on the use of 
HCC restricted tumour specific promoters, such as that for 
alpha- fetoprotein (AFP), to drive transgene expression [41]. 
The use of this type of transcriptional targeting has, however, 
failed to progress to clinical trials. The low transcriptional 
activity, particularly when compared to promoters such as 
CMV/CAG [42] and problems with their specificity [23, 
43] when used alone, has played a role in this failure. Post-
transcriptional targeting through the use of miRNA avoids 
the problems associated with the low transcriptional activity 
as any promoter can be used and specificity can be potentially 
increased through the use of TS of multiple miRNAs. This 
makes miRNA targeting potentially more promising in terms 
of moving this technology into the clinic. In many HCC 
and hepatocellular CSCs, miRNA122a is down-regulated 
compared to normal or diseased liver hepatocytes. This 
proof-of-principle study shows that exploiting miRNA122a 
allows a tumour or CSC-specific delivery of transgene, thus 
limiting dose related toxicities to normal liver. It should be 
noted that miRNA122a is liver specific therefore additional 
liver targeting strategies such as the use of modified adeno 
associated viruses [23] will be necessary if used systemically. 
MATERIALS AND METHODS
Cell culture
miRNA122a negative HCC cell lines Hep3B, PLC/
PRF/5, SKHep1, and SNU423 were obtained from ATCC 
and maintained in DMEM (Thermo Fisher Scientific, 
Scoresby, Australia) media supplemented with 10% fetal 
bovine serum (FBS) (Gibco, Australia) and 1% penicillin/
streptomycin (P/S) (Gibco). miRNA122a positive HCC 
cell line HuH7 was provided by Dr. Kim Bridle (University 
of Queensland). Cell line ID service was provided by the 
Australian Genome Research Facility (AGRF) and cell line 
genotyping was performed to confirm identity of cell lines. 
Breast cancer cell line T47D and prostate cancer cell lines 
LNCaP and DU145 were maintained in DMEM media with 
10% FCS and 1% P/S. Melanoma cell lines 92.1, Mel202, 
Mel270 (gifted by Nicholas Hayward) and ovarian cancer 
lines SKOV3, CAOV3, TOV21G were cultured in RPMI 
media (Thermo Fisher Scientific) supplemented with 10% 
FCS and 1% P/S. Human retinal pigmental epithelium 
cell line ARPE-19 was maintained in DMEM/F12 media 
(Thermo Fisher Scientific) with 10% FCS and 1% P/S. 
Cryopreserved human hepatocytes (HUCS10P) (Lonza, 
Australia) containing pooled hepatocytes from 10 donors 
were cultured as per the manufacturer’s recommendations 
in human hepatocyte maintenance media. 
Tumorsphere culture
3D tumorspheres of HuH7 were maintained in a 
serum free, stem cell conditioned NSA media as previously 
described [44]. The NSA media consisted of DMEM/
F12 supplemented with 20 ng/ml recombinant human 
epidermal growth factor (rhEGF) (Lonza), 10 ng/ml 
recombinant human basic fibroblast growth factor (rhFGF) 
(Lonza), 1% P/S (Thermo Fisher Scientific), bovine serum 
albumin (BSA) (Sigma Aldrich, St. Louis, MO, USA), and 
4 µg/ml heparin sulfate (Sigma Aldrich). Briefly, 30,000 
cells were collected, washed thrice with PBS and seeded 
in the 24 well ultra-low attachment plate (Corning, NY, 
USA). Images of the tumorspheres were taken with a 
digital camera (Olympus DP21, Japan) connected to an 
inverted microscope (Olympus CKX41) using imaging 
software (CellSens, Olympus, Japan).
Quantification of miRNA levels
Endogenous expression levels of miRNA122a was 
quantified by quantitative real time PCR (qRT-PCR) with 
Bioline Lo-Rox Sybr (Bioline, Alexandria, Australia) 
using the ViiA7 RT-PCR machine (Thermo Fisher 
Scientific) at following conditions: 95° C- 2mins followed 
by 40 cycles of 95° C- 5 s, 60° C -15 s and 70° C -15 s 
on the cDNA which was synthesized from total RNA 
isolated with trizol using the MystiCq microRNA cDNA 
Synthesis Mix (Sigma Aldrich) as per the manufacturer’s 
recommendations. MystiCq Universal PCR (MIRUP, Sigma) 
and 5′- TGGAGTGTGACAATGGTGTTTGT- 3′ primers 
were used and the levels if miRNA122a was calculated as 
number of copies per 1000 copies of human positive control 
using formula (2^(Ct control-Ct sample))*1000. Similarly, 
HCC stemness markers CD44, EpCAM, and Oct4 were 
quantified as number of copies per 1000 copies of GAPDH 
housekeeping gene using primers listed in Table 1.
Construction of expression plasmids
The gene encoding gaussia luciferase 
(GLuc) with three miRNA122a binding sites 
(ACACCATTGTCACACTCCAAC*3) at the 3′-UTR was 
artificially synthesized (Thermo Fisher Scientific). The gene 
with and without miRNA binding sites was then cloned 
in the pscAAV-GFP (a gift from John T Gray, Addgene 
plasmid # 32396) using enzymes EcoRI, StuI and EcoRI, 
EcoRV to obtain CMV-GLuc and CMV-GLuc-miR122a*3 
(Supplementary Information) respectively. Similarly, 
artificially synthesized cytosine deaminase (CD) was 
cloned in the above mentioned plasmids replacing GLuc 
to obtain CMV-CD and CMV-CD-miR122a*3.
Transfection and reporter assays
All transfection studies for studying GLuc and 
eGFP expression were performed with Lipofectamine 
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3000 (Thermo Fisher Scientific) as per the manufacturer’s 
protocol. Briefly, 30,000 cells were seeded in a 24 well plate 
and transfection was performed with 500 ng of plasmids. 72 
hours post-transfection, the amount of secreted GLuc was 
quantified with the Pierce gaussia luciferase glow assay 
kit (Thermo Fisher Scientific) as per the manufacturer’s 
recommendations. The chemiluminescence measurement 
was done with the Infinite 200 Pro NanoQuant (Tecan 
Trading AG, Switzerland). For primary human hepatocytes, 
the transfections were performed an hour after seeding 
and the amount of secreted GLuc was measured after 24 
hours. In order to account for the difference in transfection 
efficiencies across cell lines, chemiluminescence detected 
with CMV-GLuc-miR122a*3 was normalized against that 
with CMV-GLuc for individual cell type. Tumorspheres of 
HuH7 were transfected at day 3 after seeding in the NSA 
media and secreted GLuc was quantified after 48 hours. 
Similarly, to quantify the percentage of eGFP positive 
cells, flow cytometry was performed with the FACS 
Canto II and data was analysed with FCS express version 
3 (BD Biosciences; North Ryda, Australia). Percentage 
of GFP positive cells after transfection with CMV-eGFP-
miR122a*3 was normalized with CMV-eGFP.
Inhibition and overexpression of miR122a
miRNA122a inhibition experiments in primary 
hepatocytes were performed by co-transfecting miRNA122a 
inhibitor (Life technologies, Mulgrave Australia) (5pmol) and 
either CMV-GLuc or CMV-GLuc-miR122a*3 in a 24 well 
plate using Lipofectamine 3000 as per the manufacturer’s 
protocol. 24 hours post transfection, secreted GLuc was 
quantified with Pierce gaussia luciferase glow assay kit. 
Similarly, HCC cell lines Hep3B, SKHep1, PLC/PRF/5, 
and SNU423 were co-transfected with miRNA122a mimic 
(4464066, Life Technologies) (5 pmol) and either CMV-GLuc 
or CMV-GLuc-miR122*3. The amount of secreted GLuc for 
each group was reported as a percentage of CMV-GLuc. 
Cell proliferation assay
For cell proliferation assays, 10,000 cells were 
transfected with CMV-CD or CMV-CD-122a*3 in a 96 
well plate and media containing 10 µm 5-FC was added 
after 24 hours. CellTiter96 Aqueous One Solution Cell 
Proliferation Assay kit (Promega Corporation, Madison, 
WI USA) was used to quantify cell proliferation after 
48 hours of incubation with 5-FC containing media. 
Absorbance was measured at 540 nm with the Infinite 200 
Pro NanoQuant. Percentage proliferation was calculated 
for CMV-CD and CMV-CD-122a*3 for each cell line 
and percentage proliferation with CMV-CD-122a*3 was 
reported relative to CMV-CD in order to account for the 
difference in transfection efficiencies across cell lines.
Cell death assay with Annexin V/PI
To quantify cell apoptosis, flow cytometry based 
on Annexin/PI staining was used (Life Technologies). 
30,000 cells were transfected with CMV-CD and CMV-
CD-122a*3 in a 24 well plate and incubated for either 
24 hours (for tumorspheres) or 48 hours (adherent cells) 
with 10 µm 5-FC containing media. Cells were then 
washed with PBS, collected and co-stained with Annexin 
V and PI as recommended by the manufacturer. Annexin 
V/PI positive cells were quantified with the FACS Canto II 
and data analysis was performed with FCS express 3. The 
percentage of apoptotic cells after transfection with CMV-
CD-122a*3 was normalized with CMV-CD. 
Statistical analysis
All experiments were repeated at least thrice in 
triplicates and results were presented as mean ± SD. Two-
tailed student’s t-test was performed to test the difference 
between groups (GraphPad Prism v7) (* < 0.05, ** < 0.01, 
*** < 0.001).
Abbreviations
CD: Cytosine deaminase; CSC: cancer stem cells; 
FC: fluorocytosine; GDEPT: gene directed enzyme 
prodrug therapy; HCC: hepatocellular carcinoma; 
GLuc: gaussia luciferase; miRNA: microRNA: UTR: 
untranslated region.
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Table 1: Primers used for qRT-PCR studies
Gene Forward primer Reverse Primer
GAPDH 5′-TCCTGCACCACCAACTGCTTAGC-3′ 5′- GCCTGCTTCACCACCTTCTTGAT-3′
CD44 5′-CCAGAAGGAACAGTGGTTTGGC-3′ 5′-ACTGTCCTCTGGGCTTGGTGTT-3′
CD90 5′-GAAGGTCCTCTACTTATCCGCC-3′ 5′-TGATGCCCTCACACTTGACCAG-3′
CD133 5′-CACTACCAAGGACAAGGCGTTC-3′ 5′-CAACGCCTCTTTGGTCTCCTTG-3′
Oct4 5′-CTTCTGCTTCAGGAGCTTGG-3′ 5′-GAAGGAGAAGCTGGAGCAAA-3′
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